Abstract
Objectives
Diagnosis of light chain amyloidosis (AL) requires demonstration of amyloid deposits in a tissue biopsy followed by appropriate typing. Previous studies demonstrated increased dimerization of monoclonal serum free light chains (FLCs) as a pathological feature of AL. To further examine the pathogenicity of FLC, we aimed at testing amino acid sequence homology between circulating and deposited light chains (LCs).
Methods
Matched tissue biopsy and serum of 10 AL patients were subjected to tissue proteomic amyloid typing and nephelometric FLC assay, respectively. Serum FLC monomers (M) and dimers (D) were analyzed by Western blotting (WB) and mass spectrometry (MS).
Results
WB of serum FLCs showed predominance of either κ or λ type, in agreement with the nephelometric assay data. Abnormal FLC M–D patterns typical of AL amyloidosis were demonstrated in 8 AL-λ patients and in one of two AL-κ patients: increased levels of monoclonal FLC dimers, high D/M ratio values of involved FLCs, and high ratios of involved to uninvolved dimeric FLCs. MS of serum FLC dimers showed predominant constant domain sequences, in concordance with the tissue proteomic amyloid typing. Most importantly, variable domain sequence homology between circulating and deposited LC species was demonstrated, mainly in AL-λ cases.
Conclusions
This is the first study to demonstrate homology between circulating FLCs and tissue-deposited LCs in AL-λ amyloidosis. The applied methodology can facilitate studying the pathogenicity of circulating FLC dimers in AL amyloidosis. The study also highlights the potential of FLC monomer and dimer analysis as a non-invasive screening tool for this disease.
-
Research ethics: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ Institutional Review Board (21-010372).
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: The authors state no conflict of interest.
-
Research funding: The study is supported by Pfizer Global Medical Grants; program 65925007.
-
Data availability: The raw data can be obtained on request from the corresponding author.
References
1. Buxbaum, JN, Dispenzieri, A, Eisenberg, DS, Fändrich, M, Merlini, G, Saraiva, MJM, et al.. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2022;29:213–9. https://doi.org/10.1080/13506129.2022.2147636.Search in Google Scholar PubMed
2. Baker, KR. Light chain amyloidosis: epidemiology, staging, and prognostication. Methodist Debakey Cardiovasc J 2022;18:27–35. https://doi.org/10.14797/mdcvj.1070.Search in Google Scholar PubMed PubMed Central
3. Schönland, SO, Hegenbart, U, Bochtler, T, Mangatter, A, Hansberg, M, Ho, AD, et al.. Immunohistochemistry in the classification of systemic forms of amyloidosis: asystematic investigation of 117 patients. Blood 2012;119:488–93. https://doi.org/10.1182/blood-2011-06-358507.Search in Google Scholar PubMed
4. Linke, RP, Oos, R, Wiegel, NM, Nathrath, WB. Classification of amyloidosis: misdiagnosis by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006;108:197–08. https://doi.org/10.1016/j.acthis.2006.03.010.Search in Google Scholar PubMed
5. Leung, N, Nasr, SH, Sethi, S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012;120:3206–13. https://doi.org/10.1182/blood-2012-03-413682.Search in Google Scholar PubMed
6. Linke, RP. On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 2012;47:61–132. https://doi.org/10.1016/j.proghi.2012.03.001.Search in Google Scholar PubMed
7. Chee, CE, Lacy, MQ, Dogan, A, Zeldenrust, SR, Gertz, MA. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk 2010;10:177–80. https://doi.org/10.3816/clml.2010.n.027.Search in Google Scholar PubMed
8. de Larrea, CF, Verga, L, Morbini, P, Klersy, C, Lavatelli, F, Folli, A, et al.. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015;125:2239–44. https://doi.org/10.1182/blood-2014-11-609883.Search in Google Scholar PubMed
9. Verga, L, Morbini, P, Palladini, G, Obici, L, Capello, GL, Paulli, M, et al.. The role of immuno-electron microscopy in amyloid typing: the experience of the pavia referral center. In: Picken, M, Herrera, G, Dogan, A, editors. Amyloid and related disorders. Current clinical pathology. Cham: Humana Press; 2015:299–310 pp.10.1007/978-3-319-19294-9_22Search in Google Scholar
10. Mollee, P, Boros, S, Loo, D, Ruelcke, JE, Lakis, VA, Lê Cao, K-A, et al.. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clin Proteom 2016;13:30. https://doi.org/10.1186/s12014-016-9133-x.Search in Google Scholar PubMed PubMed Central
11. Abildgaard, N, Rojek, AM, Møller, HEH, Palstrøm, NB, Nyvold, CG, Rasmussen, LM, et al.. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits. Amyloid 2020;27:59–66. https://doi.org/10.1080/13506129.2019.1688289.Search in Google Scholar PubMed
12. Vrana, JA, Gamez, JD, Madden, BJ, Theis, JD, Bergen, HR3rd, Dogan, A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–9. https://doi.org/10.1182/blood-2009-07-230722.Search in Google Scholar PubMed
13. Muchtar, E, Dispenzieri, A, Lacy, MQ, Buadi, FK, Kapoor, P, Hayman, SR, et al.. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 2017;49:545–51. https://doi.org/10.1080/07853890.2017.1304649.Search in Google Scholar PubMed
14. Muchtar, E, Gertz, MA, Kyle, RA, Lacy, MQ, Dingli, D, Leung, N, et al.. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc 2019;94:472–83. Erratum in: Mayo Clin Proc 2019;94:1121. https://doi.org/10.1016/j.mayocp.2018.08.006.Search in Google Scholar PubMed
15. Lachmann, HJ, Booth, DR, Booth, SE, Bybee, A, Gilbertson, J, Gillmore, JD, et al.. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–91. https://doi.org/10.1056/nejmoa013354.Search in Google Scholar PubMed
16. Kaplan, B, Ramirez-Alvarado, M, Sikking, L, Golderman, S, Dispenzieri, A, Livneh, A, et al.. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 2009;144:705–15. https://doi.org/10.1111/j.1365-2141.2008.07522.x.Search in Google Scholar PubMed
17. Kaplan, B, Golderman, S, Aizenbud, B, Esev, K, Kukuy, O, Leiba, M, et al.. Immunoglobulin free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study. Am J Hematol 2014;89:882–8. https://doi.org/10.1002/ajh.23773.Search in Google Scholar PubMed
18. Kukuy, O, Kaplan, B, Golderman, S, Volkov, A, Duek, A, Leiba, M, et al.. Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis. Clin Exp Nephrol 2019;23:776–2. https://doi.org/10.1007/s10157-019-01699-5.Search in Google Scholar PubMed
19. Gatt, ME, Kaplan, B, Yogev, D, Slyusarevsky, E, Pogrebijski, G, Golderman, S, et al.. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. Br J Haematol 2018;182:86–92. https://doi.org/10.1111/bjh.15387.Search in Google Scholar PubMed
20. Dasari, S, Theis, JD, Vrana, JA, Rech, KL, Dao, LN, Howard, MT, et al.. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc 2020;95:1852–64. https://doi.org/10.1016/j.mayocp.2020.06.029.Search in Google Scholar PubMed
21. Tabb, DL, Fernando, CG, Chambers, MC. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J Proteome Res 2007;6:654–61. https://doi.org/10.1021/pr0604054.Search in Google Scholar PubMed PubMed Central
22. Ma, ZQ, Dasari, S, Chambers, MC, Litton, MD, Sobecki, SM, Zimmerman, LJ, et al.. IDPicker 2.0: improved protein assembly with high discrimination peptide identification filtering. J Proteome Res 2009;8:3872–81. https://doi.org/10.1021/pr900360j.Search in Google Scholar PubMed PubMed Central
23. Kourelis, TV, Dasari, S, Theis, JD, Ramirez-Alvarado, M, Kurtin, PJ, Gertz, MA, et al.. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood 2017;29:299–306. https://doi.org/10.1182/blood-2016-10-743997.Search in Google Scholar PubMed
24. Baur, J, Berghaus, N, Schreiner, S, Hegenbart, U, Schönland, SO, Wiese, S, et al.. Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. Amyloid 2022;30:27–37. https://doi.org/10.1080/13506129.2022.2095618.Search in Google Scholar PubMed
25. Baden, EM, Owen, BAL, Peterson, FC, Volkman, BF, Ramirez-Alvarado, M, Thompson, JR. Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem 2008;283:15853–60. https://doi.org/10.1074/jbc.m705347200.Search in Google Scholar
26. Martin, DJ, Ramirez-Alvarado, M. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. Amyloid 2010;17:129–36. https://doi.org/10.3109/13506129.2010.530081.Search in Google Scholar PubMed PubMed Central
27. Ramirez-Alvarado, M. Amyloid formation in light chain amyloidosis. Curr Top Med Chem 2012;12:2523–33. https://doi.org/10.2174/1568026611212220007.Search in Google Scholar PubMed PubMed Central
28. Berghaus, N, Schreiner, S, Granzow, M, Müller-Tidow, C, Hegenbart, U, Schönland, SO, et al.. Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS One 2022;17:e0264407. https://doi.org/10.1371/journal.pone.0264407.Search in Google Scholar PubMed PubMed Central
29. Swuec, P, Lavatelli, F, Tasaki, M, Paissoni, C, Rognoni, P, Maritan, M, et al.. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun 2019;10:1269. https://doi.org/10.1038/s41467-019-09133-w.Search in Google Scholar PubMed PubMed Central
30. Connors, LH, Jiang, Y, Budnik, M, Theberge, R, Prokaeva, T, Bodi, KL, et al.. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry 2007;46:14259–71. https://doi.org/10.1021/bi7013773.Search in Google Scholar PubMed PubMed Central
31. Dispenzieri, A, Larson, DR, Rajkumar, SV, Kyle, RA, Kumar, SK, Kourelis, T, et al.. N-Glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia 2020;34:2749–53. https://doi.org/10.1038/s41375-020-0940-8.Search in Google Scholar PubMed PubMed Central
32. Mellors, PW, Dasari, S, Kohlhagen, MC, Kourelis, T, Go, RS, Muchtar, E, et al.. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J 2021;11:50. Erratum in: Blood Cancer J 2021;11:110.10.1038/s41408-021-00444-0Search in Google Scholar PubMed PubMed Central
33. Campbell, L, Simpson, D, Ramasamy, K, Sadler, R. Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. Clin Biochem 2021;95:81–3. https://doi.org/10.1016/j.clinbiochem.2021.05.012.Search in Google Scholar PubMed
34. Fedotov, SA, Khrabrova, MS, Anpilova, AO, Dobronravov, VA, Rubel, AA. Noninvasive diagnostics of renal amyloidosis: current state and perspectives. Int J Mol Sci 2022;23:12662. https://doi.org/10.3390/ijms232012662.Search in Google Scholar PubMed PubMed Central
35. Lavatelli, F, Brambilla, F, Valentini, V, Rognoni, P, Casarini, S, Di Silvestre, D, et al.. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 2011;1814:409–19. https://doi.org/10.1016/j.bbapap.2010.12.012.Search in Google Scholar PubMed
36. Radamaker, L, Baur, J, Huhn, S, Haupt, C, Hegenbart, U, Schönland, S, et al.. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nat Commun 2021;12:875. https://doi.org/10.1038/s41467-021-21126-2.Search in Google Scholar PubMed PubMed Central
37. Migrino, RQ, Hari, P, Gutterman, DD, Bright, M, Truran, S, Schlundt, B, et al.. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol 2010;145:67–8. https://doi.org/10.1016/j.ijcard.2009.04.044.Search in Google Scholar PubMed PubMed Central
38. Sharma, A, Tripathi, M, Satyam, A, Kumar, L. Study on antioxidant level in patients with multiple myeloma. Leuk Lymphoma 2009;50:809–15. https://doi.org/10.1080/10428190902802323.Search in Google Scholar PubMed
39. Wilkinson, B, Gilbert, H. Protein disulfide isomerase. Biochem Biophys Acta Proteins Proteomics 2004;1699:35–44. https://doi.org/10.1016/s1570-9639(04)00063-9.Search in Google Scholar
40. Xiao, R, Lundstrom-Ljung, J, Holmgren, A, Gilbert, HF. Catalysis of thiol/disulfide exchange. J Biol Chem 2005;280:21099–106. https://doi.org/10.1074/jbc.m411476200.Search in Google Scholar
41. Qin, Z, Hu, D, Zhu, M, Fink, AL. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry 2007;46:3521–31. https://doi.org/10.1021/bi061716v.Search in Google Scholar PubMed
42. Souillac, PO, Uversky, VN, Millett, IS, Khurana, R, Doniach, S, Fink, AL. Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation: evidence for an off-pathway oligomer at acidic pH. J Biol Chem 2002;277:12666–79. https://doi.org/10.1074/jbc.m109229200.Search in Google Scholar
43. Rottenaicher, GJ, Ramona, M, Absmeier, RM, Meier, L, Zacharias, M, Buchner, J. A constant domain mutation in a patient-derived antibody light chain reveals principles of a constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis. Commun Biol 2023;6:209. https://doi.org/10.1038/s42003-023-04574-y.Search in Google Scholar PubMed PubMed Central
© 2023 Walter de Gruyter GmbH, Berlin/Boston
